Three companies have led the pack in microbiome startup investments over the past five years. This is who they are and what they invest in.

Artist's impression of gut microflora

Johnson & Johnson, the US-based pharmaceuticals company, has been one of the most active investors in microbiome-based startups over the past five years, followed by Royal DSM, the Dutch nutrition, health and beauty company.

Johnson & Johnson’s, for example, was an early backer of DayTwo, an Israeli startup that uses sequencing of the gut biome to create personalised nutritional advice to help people with type 2 diabetes stabilise their blood sugar levels. The company has raised $90m, with the most recent round in May 2021. Samsung Next is also one of the backers.

Johnson & Johnson has also backed Infinant Health, a California-based company that sells a probiotic that helps babies establish a healthy gut microbiome. The product is based on research that…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Maija Palmer

Maija Palmer is editor of Global Venturing and puts together the weekly email newsletter (sign up here for free).